Literature DB >> 31094590

Surgical treatment, complications, and reimbursement among patients with clavicle fracture and acromioclavicular dislocations: a US retrospective claims database analysis.

Matthew Putnam1,2,3, Mollie Vanderkarr4, Piyush Nandwani5, Chantal E Holy6, Abhishek S Chitnis6.   

Abstract

Aims: To assess rates of surgical treatment, post-surgical complications, reoperations, and reimbursement in patients with clavicle fractures and acromioclavicular (AC) dislocations. Materials and methods: This US retrospective study used data from patients with ≥1 diagnosis of clavicle fracture or AC dislocation (index) between 2012-2016. Surgical treatment was defined as a procedure within 4 weeks after clavicle fracture/AC dislocation. Rates of complications (infection, non-union, mal-union), reoperations (device removal or revisions), and all-cause healthcare reimbursement (adjusted to 2016$) were evaluated 2 years post-index among surgical patients.
Results: A total of 95,243 patients with clavicle fracture and 52,100 patients with AC dislocation were identified. Mean (SD) age for clavicle fracture and AC dislocation was 23.8 (18.6) and 33.0 (15.6) years, respectively. Most clavicle fracture and AC dislocation patients were male (70.9% and 78.0%, respectively), and had few comorbidities (86.4% and 84.8% had a Charlson Comorbidity Index = 0 and 73.1% and 66.0% had Elixhauser = 0, respectively). Only 15.2% of clavicle fracture and 5.3% of AC dislocation patients received surgical treatment. Among patients undergoing surgical treatment, 2-year rates of infection, non-union, and mal-union were 1.0%, 4.2%, and 0.9%, respectively, for clavicle fracture, and 2.0%, 0.9%, and 0.1%, respectively, for AC dislocation. Reoperations occurred in 83.0% of clavicle fracture and 67.5% of AC dislocation patients. Mean (SD) 2-year reimbursement was $27,635 ($68,173) for clavicle fracture and $23,096 ($28,746) for AC dislocation. Limitations: Administrative claims data lack clinical information, limiting inferences that can be made. This data may not be generalizable to other patients. Conclusions: Rates of surgical treatment for clavicle fractures and AC dislocation and rates of infection, non-union, and mal-union among surgically-treated patients were low. However, surgical patients had high rates of device removal or revision surgery during 2-year follow-up. Improved surgical methods and technologies could reduce non-planned reoperations and device removals, thereby reducing healthcare system costs.

Entities:  

Keywords:  Clavicle fracture; D00; I19; acromioclavicular joint; complications; infection; mal-union; non-union; reimbursement; reoperation; surgery

Mesh:

Year:  2019        PMID: 31094590     DOI: 10.1080/13696998.2019.1620245

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  3 in total

Review 1.  Nonanatomic and Suture-Based Coracoclavicular Joint Stabilization Techniques Provide Adequate Stability at a Lower Cost of Implants in Biomechanical Studies When Compared With Anatomic Techniques: A Systematic Review and Meta-Analysis.

Authors:  Theodorakys Marín Fermín; Jean Michel Hovsepian; Víctor Miguel Rodrigues Fernandes; Ioannis Terzidis; Emmanouil Papakostas; Jason Koh
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-02-24

2.  Surgical treatment, complications, reoperations, and healthcare costs among patients with clavicle fracture in England.

Authors:  Simone Wolf; Abhishek S Chitnis; Anandan Manoranjith; Mollie Vanderkarr; Javier Quintana Plaza; Laura V Gador; Chantal E Holy; Charisse Sparks; Simon M Lambert
Journal:  BMC Musculoskelet Disord       Date:  2022-02-09       Impact factor: 2.362

3.  The variance of clavicular surface morphology is predictable: an analysis of dependent and independent metadata variables.

Authors:  Arabella D Fontana; Harry A Hoyen; Michael Blauth; André Galm; Marcel Schweizer; Christoph Raas; Martin Jaeger; Chunyan Jiang; Stefaan Nijs; Simon Lambert
Journal:  JSES Int       Date:  2020-06-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.